WO2009064681A2 - Liquid compositions comprising valsartan - Google Patents
Liquid compositions comprising valsartan Download PDFInfo
- Publication number
- WO2009064681A2 WO2009064681A2 PCT/US2008/082932 US2008082932W WO2009064681A2 WO 2009064681 A2 WO2009064681 A2 WO 2009064681A2 US 2008082932 W US2008082932 W US 2008082932W WO 2009064681 A2 WO2009064681 A2 WO 2009064681A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- liquid oral
- eur
- usp
- valsartan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- This invention relates to pharmaceutical compositions for the treatment of angiotensin II mediated disorders and conditions comprising valsartan or a pharmaceutically acceptable salt thereof suitable for oral administration, and methods of treatment of angiotensin Il mediated disorders and conditions by the oral administration of such pharmaceutical compositions of valsartan.
- the present invention is directed to a composition for the treatment of angiotensin II mediated disorders and conditions, the composition comprising a solution of valsartan.
- Valsartan or ((S)- ⁇ /-valeryl- ⁇ /- ⁇ [2'-(1H-tetrazole-5-yl)-biphenyl- 4-yl]-methyl ⁇ -valine) suitable for use in the present invention can be purchased from commercial sources or can be prepared according to known methods.
- the preparation of Valsartan is described in U.S. Patent No. 5,399,578, the entire disclosure of which is incorporated by reference herein.
- Valsartan may be used for purposes of this invention in its free form as well as in any suitable salt form.
- Valsartan also included within the scope of the present invention are the salts, esters, amides, prodrugs, active metabolites, analogs, and the like of Valsartan, particularly the calcium salt of Valsartan.
- a detailed description of the calcium salt and process of making are disclosed in published U.S. Patent Application No. 2003/0207930, the contents of which are fully incorporated by reference herein in their entirety.
- the present invention is also directed to methods for treating an angiotensin Il mediated disorder or condition comprising administering an effective amount of the compositions of the invention, i.e., a liquid oral dosage formulation comprising valsartan.
- a genus of compounds, including valsartan may be employed to treat hypertension, congestive heart failure, angina, myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, stroke, left ventricular hypertrophy, cognitive dysfunction, headache, or chronic heart failure by
- a shelf-stable liquid oral dosage formulation comprising valsartan can be prepared.
- the valsartan drug substance is relatively water insoluble and also degrades in water, and so the ability to produce a shelf-stable formulation was unexpected.
- the liquid oral dosage formulations comprising valsartan are preferably solutions of valsartan. Valsartan concentration is between about 1 mg/ml to about 5 mg/ml, preferably about 3 mg/ml.
- the formulations of the invention can also contain a wetting agent, e.g., polysorbate 80, poloxamers, including poloxamer 188, polyethoxylated castor oil and polyethoxylated hydrogenated castor oil, and polyoxyl 40 stearate.
- Poloxamer 188 has the structure HO(CH 2 CH 2 O) a (CH(CH 3 )CH 2 OH) b (CH 2 CH 2 O) c H, where a is 75, b is 30, and c is 75, with an average molecular weight of about 8350.
- the wetting agent is present in amounts typically between about 0.1 % and about 5%, or between about 0.2% and about 1%, or between about 0.5%
- the pH of the formulation can range between about 4.5 and 7.0, preferably between about 5.5 and about 6.5, even more preferably between about 5.5 and about 6.0 or between about 5.7 and about 6.2, most preferably about 5.9.
- Suitable buffers include, e.g., alkaline metal citrate buffers, such as alkaline metal citrate salts with citric acid, alkaline metal acetate buffers, such as sodium acetate salts with acetic acid, and alkaline metal succinate buffers, such as sodium succinate salts with succinic acid, and mixtures thereof.
- alkaline metal citrate buffers such as alkaline metal citrate salts with citric acid
- alkaline metal acetate buffers such as sodium acetate salts with acetic acid
- alkaline metal succinate buffers such as sodium succinate salts with succinic acid, and mixtures thereof.
- Preferred buffers include citric acid and sodium citrate.
- the formulations typically contain an antifoaming agent, e.g., simethicone, typically added as an emulsion, e.g., a 30% emulsion.
- an antifoaming agent e.g., simethicone
- emulsion e.g., a 30% emulsion.
- a 30% emulsion can be added at a concentration of about 0.1% to about 0.25% in the final formulation.
- Sweeteners such as mannitol, sucralose, saccharin, sodium saccharin, aspartame, sucralose, acesulfame potassium, glucose, fructose, lactitol, maltitol, maltose, sorbitol, sucrose, and xylitol can be used.
- Flavoring agents can also be added to improve compliance.
- Suitable preservatives for oral solutions include, e.g., benzoic acid, sorbic acid (and salts thereof), parabens (butyl, ethyl, methyl, propyl), sodium benzoate, and sodium propionate.
- a preservative such as those set forth above, or a mixture thereof, can be present in amounts between about 0.01% and about 0.5%; or between about 0.02% and 0.25%; or between about 0.1% and about 0.2%.
- the formulation comprises about 0.02% propyl paraben and about 0.18% methyl paraben.
- compositions comprising 0.03% propyl paraben and 0.12% methyl paraben, 0.148% methylparaben and 0.016% propylparaben and formulations comprising 0.16% methyl paraben and 0.2% potassium sorbate.
- the solutions of the invention can be made in conventional liquid formulation equipment.
- the solution of the invention is produced by a process comprising admixing water, drug substance, followed by the addition and admixture of buffer components, sweeteners, and flavouring agents.
- buffer components preservatives, sweetener, flavour, and the buffer components are dissolved in water.
- methylparaben and valsartan drug substance may be dissolved in propylene glycol, with heat, to form a solution.
- This propylene glycol solution is then admixed with the aqueous portion and a final solution is prepared.
- the buffer components can be adjusted to produce the desired solution pH. A pH of between about 4.5 and 7.0 provides a solution with the most stable drug substance.
- Poloxamer 188 preservatives, sweetener, flavour, and the buffer components are dissolved in water, followed by the addition of the valsartan drug substance, with heat up to 90 0 C, and a solution formed.
- the following formulations can be prepared as indicated above, using the following ingredients:
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010123691/15A RU2488393C2 (en) | 2007-11-12 | 2008-11-10 | Liquid compositions containing valsartan |
CN200880115379A CN101854913A (en) | 2007-11-12 | 2008-11-10 | Pharmaceutical compositions |
EP08850984A EP2222273A2 (en) | 2007-11-12 | 2008-11-10 | Liquid compositions comprising valsartan |
AU2008321159A AU2008321159B2 (en) | 2007-11-12 | 2008-11-10 | Liquid compositions comprising valsartan |
CA2705453A CA2705453A1 (en) | 2007-11-12 | 2008-11-10 | Pharmaceutical compositions |
MX2010005198A MX2010005198A (en) | 2007-11-12 | 2008-11-10 | Pharmaceutical compositions. |
JP2010533312A JP2011503105A (en) | 2007-11-12 | 2008-11-10 | Valsartan-containing liquid composition |
US12/741,857 US20100267787A1 (en) | 2007-11-12 | 2008-11-10 | Pharmaceutical Compositions |
BRPI0820198A BRPI0820198A2 (en) | 2007-11-12 | 2008-11-10 | pharmaceutical compositions |
US13/721,521 US20130109729A1 (en) | 2007-11-12 | 2012-12-20 | Pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98717807P | 2007-11-12 | 2007-11-12 | |
US60/987,178 | 2007-11-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/721,521 Continuation US20130109729A1 (en) | 2007-11-12 | 2012-12-20 | Pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009064681A2 true WO2009064681A2 (en) | 2009-05-22 |
WO2009064681A3 WO2009064681A3 (en) | 2009-10-08 |
Family
ID=40639403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/082932 WO2009064681A2 (en) | 2007-11-12 | 2008-11-10 | Liquid compositions comprising valsartan |
Country Status (10)
Country | Link |
---|---|
US (2) | US20100267787A1 (en) |
EP (2) | EP2316422A1 (en) |
JP (1) | JP2011503105A (en) |
KR (1) | KR20100087002A (en) |
CN (1) | CN101854913A (en) |
BR (1) | BRPI0820198A2 (en) |
CA (1) | CA2705453A1 (en) |
MX (1) | MX2010005198A (en) |
RU (2) | RU2488393C2 (en) |
WO (1) | WO2009064681A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013098268A3 (en) * | 2011-12-26 | 2013-08-22 | Novartis Ag | Tablets and dry-coated agents |
US10478422B1 (en) | 2018-12-14 | 2019-11-19 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US11413275B1 (en) | 2018-12-14 | 2022-08-16 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US11446243B1 (en) | 2019-08-05 | 2022-09-20 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101993436B1 (en) * | 2011-10-31 | 2019-06-26 | 노바르티스 아게 | Pazopanib formulation |
ES2584248B1 (en) * | 2015-03-24 | 2017-04-19 | Farmalider, S.A. | Pharmaceutical composition of sildenafil citrate in suspension form for oral use |
CN105596305A (en) * | 2015-12-25 | 2016-05-25 | 华润赛科药业有限责任公司 | High-stability valsartan preparation and preparation method thereof |
WO2017191619A2 (en) * | 2016-05-06 | 2017-11-09 | Sun Pharmaceutical Industries Limited | A process for the preparation of a salt of sacubitril and valsartan |
WO2018204040A1 (en) * | 2017-05-01 | 2018-11-08 | Bioramo, Llc | Oral liquid compositions of valsartan |
US10548838B1 (en) | 2018-12-14 | 2020-02-04 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009048848A1 (en) * | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL97219A (en) | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
PE20020613A1 (en) | 2000-07-19 | 2002-08-07 | Novartis Ag | SALTS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-IL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOLE-5-IL) -BIPHENYL-4-ILMETHYL] -AMINE AS ANTAGONIST OF THE AT1 RECEPTOR |
RS52904A (en) * | 2001-12-20 | 2006-12-15 | Bristol-Myers Squib Company | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
US20040247588A1 (en) * | 2002-08-28 | 2004-12-09 | Johnson Robert E. | Formulations of modified antibodies and methods of making the same |
TWI327913B (en) * | 2003-03-12 | 2010-08-01 | Novartis Ag | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
EP1691788A2 (en) * | 2003-11-21 | 2006-08-23 | Schering Corporation | Phosphodiesterase v inhibitor formulations |
US20070026026A1 (en) * | 2005-08-01 | 2007-02-01 | David Delmarre | Oral liquid losartan compositions |
-
2008
- 2008-11-10 US US12/741,857 patent/US20100267787A1/en not_active Abandoned
- 2008-11-10 EP EP10177744A patent/EP2316422A1/en not_active Withdrawn
- 2008-11-10 EP EP08850984A patent/EP2222273A2/en not_active Withdrawn
- 2008-11-10 KR KR1020107010332A patent/KR20100087002A/en not_active Application Discontinuation
- 2008-11-10 CA CA2705453A patent/CA2705453A1/en not_active Abandoned
- 2008-11-10 CN CN200880115379A patent/CN101854913A/en active Pending
- 2008-11-10 MX MX2010005198A patent/MX2010005198A/en unknown
- 2008-11-10 BR BRPI0820198A patent/BRPI0820198A2/en not_active IP Right Cessation
- 2008-11-10 RU RU2010123691/15A patent/RU2488393C2/en not_active IP Right Cessation
- 2008-11-10 JP JP2010533312A patent/JP2011503105A/en active Pending
- 2008-11-10 WO PCT/US2008/082932 patent/WO2009064681A2/en active Application Filing
-
2012
- 2012-12-20 US US13/721,521 patent/US20130109729A1/en not_active Abandoned
-
2013
- 2013-01-11 RU RU2013101018/15A patent/RU2013101018A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009048848A1 (en) * | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
Non-Patent Citations (2)
Title |
---|
FLESCH G ET AL: "Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 52, no. 2, 1997, pages 115-120, XP002535608 ISSN: 0031-6970 * |
MBAH C J: "Solubilization of valsartan by aqueous glycerol, polyethylene glycol and micellar solutions" PHARMAZIE, vol. 61, no. 4, April 2006 (2006-04), pages 322-324, XP9118979 ISSN: 0031-7144 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013098268A3 (en) * | 2011-12-26 | 2013-08-22 | Novartis Ag | Tablets and dry-coated agents |
US10478422B1 (en) | 2018-12-14 | 2019-11-19 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US10973802B2 (en) | 2018-12-14 | 2021-04-13 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US11413275B1 (en) | 2018-12-14 | 2022-08-16 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US11446243B1 (en) | 2019-08-05 | 2022-09-20 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
Also Published As
Publication number | Publication date |
---|---|
JP2011503105A (en) | 2011-01-27 |
EP2222273A2 (en) | 2010-09-01 |
RU2013101018A (en) | 2014-07-20 |
KR20100087002A (en) | 2010-08-02 |
MX2010005198A (en) | 2010-05-20 |
RU2010123691A (en) | 2011-12-20 |
US20100267787A1 (en) | 2010-10-21 |
EP2316422A1 (en) | 2011-05-04 |
RU2488393C2 (en) | 2013-07-27 |
BRPI0820198A2 (en) | 2019-09-24 |
US20130109729A1 (en) | 2013-05-02 |
CN101854913A (en) | 2010-10-06 |
WO2009064681A3 (en) | 2009-10-08 |
AU2008321159A1 (en) | 2009-05-22 |
CA2705453A1 (en) | 2009-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130109729A1 (en) | Pharmaceutical composition | |
US10201519B2 (en) | Stabilized pediatric suspension of carisbamate | |
US20090048344A1 (en) | Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid | |
KR100292124B1 (en) | Oral Compositions Containing Ondansetron | |
US11529333B2 (en) | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof | |
US20060269598A1 (en) | Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use | |
US11738020B2 (en) | Stable liquid vigabatrin pharmaceutical composition for oral dosage | |
US7691880B2 (en) | Methylphenidate solution and associated methods of administration and production | |
US20060198856A1 (en) | Ibuprofen suspension stabilized with docusate sodium | |
DE10038364A1 (en) | Pharmaceutical effervescent formulation containing ramipril | |
AU2008321159B2 (en) | Liquid compositions comprising valsartan | |
EP2481395A1 (en) | Sachet, effervescent tablet and dry syrup of otilonium | |
US20060100271A1 (en) | Stabilized aqueous ranitidine compositions | |
US20220339124A1 (en) | Intranasal pharmaceutical compositions of cyclobenzaprine | |
WO2014191414A1 (en) | Syrup formulation of salbutamol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880115379.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08850984 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008850984 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008321159 Country of ref document: AU Ref document number: 2687/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12741857 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20107010332 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2705453 Country of ref document: CA Ref document number: 2010533312 Country of ref document: JP Ref document number: MX/A/2010/005198 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2008321159 Country of ref document: AU Date of ref document: 20081110 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010123691 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0820198 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100511 |